Skip to main
KYTX

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics is a promising biopharmaceutical company with a strong product candidate in a new and potentially lucrative market. Their current valuation and risks are well managed, with a solid financial outlook that includes a 13% discount rate and 1% terminal growth rate. Their expected approval chances for their top three indications, as well as their FDA alignment, provide further confidence in their potential success. However, risks such as lack of durable responses and long-term dilution could potentially impact the company's future success.

Bears say

Kyverna Therapeutics is a clinical-stage biopharmaceutical company that has a negative outlook due to its limited product pipeline, high development costs, and competitive market for autoimmune therapies. Despite its successful clinical trials for SPS and gMG, the company may struggle to gain market share and generate significant revenues due to the smaller size of its potential patient populations and the presence of established competitors with similar treatments. Additionally, the company has yet to receive FDA approval for any of its products, and its financial statements show minimal revenues and high operating costs, raising concerns about its ability to sustain operations and continue development.

KYTX has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 4 analysts, KYTX has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.